Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases.

Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Scoville E, Konijeti GG, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP.

Clin Gastroenterol Hepatol. 2014 Nov;12(11):1905-10. doi: 10.1016/j.cgh.2014.02.034. Epub 2014 Mar 12.

2.

Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors.

Scoville EA, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, Ananthakrishnan AN.

Inflamm Bowel Dis. 2014 Apr;20(4):631-6. doi: 10.1097/MIB.0000000000000007.

3.

Overwhelmed patients: a videographic analysis of how patients with type 2 diabetes and clinicians articulate and address treatment burden during clinical encounters.

Bohlen K, Scoville E, Shippee ND, May CR, Montori VM.

Diabetes Care. 2012 Jan;35(1):47-9. doi: 10.2337/dc11-1082. Epub 2011 Nov 18.

4.

Why do women reject bisphosphonates for osteoporosis? A videographic study.

Scoville EA, Ponce de Leon Lovaton P, Shah ND, Pencille LJ, Montori VM.

PLoS One. 2011 Apr 13;6(4):e18468. doi: 10.1371/journal.pone.0018468.

5.

Surfactant protein-D and surfactant inhibit endotoxin-induced pulmonary inflammation.

Ikegami M, Scoville EA, Grant S, Korfhagen T, Brondyk W, Scheule RK, Whitsett JA.

Chest. 2007 Nov;132(5):1447-54. Epub 2007 Oct 9.

PMID:
17925426

Supplemental Content

Loading ...
Support Center